Physician profile
James Sweet
NPI 1760429781
$7,326.47
in general payments reported to CMS, 2019-2025
35 companies · $49.88 in 2025
The $49.88 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,902 · 2020: $1,044 · 2021: $1,774 · 2022: $2,075 · 2023: $129 · 2024: $352 · 2025: $49.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $517 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $517.47 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,029.20 | 2019-2025 | Nucala |
| Abbvie INC. | $628.28 | 2019-2022 | |
| Csl Behring | $589.02 | 2019-2022 | |
| Janssen Biotech, INC. | $527.60 | 2020-2022 | |
| Genzyme Corporation | $512.72 | 2019-2024 | |
| Octapharma USA, INC. | $509.02 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $493.51 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $398.83 | 2019-2024 | Airsupra, Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $338.65 | 2020-2024 | Eohilia |
| Pfizer INC. | $272.22 | 2019-2022 | |
| Lilly USA, LLC | $268.07 | 2019-2022 | |
| Kaleo, INC. | $249.19 | 2020-2022 | |
| Bio Products Laboratory USA, INC. | $155.37 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $127.76 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $118.39 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $103.41 | 2019-2022 | |
| Ucb, INC. | $102.70 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.33 | 2020-2021 | |
| Grifols USA, LLC | $100.37 | 2019-2024 | Xembify |
| Optinose US, INC. | $99.74 | 2019-2021 | |
| Genentech, INC. | $99.16 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $80.54 | 2020-2022 | |
| Incyte Corporation | $46.75 | 2021-2022 | |
| Celgene Corporation | $43.13 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $42.27 | 2019 | |
| Blueprint Medicines Corporation | $37.35 | 2022-2024 | Ayvakit |
| Shire North American Group INC | $35.73 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $32.34 | 2019 | |
| Biofrontera INC. | $30.36 | 2019-2021 | |
| 3b Medical, INC. | $30.15 | 2025 | Luna |
| Alk-Abello, INC | $29.17 | 2022 | |
| Leo Pharma INC. | $25.58 | 2022 | |
| Amgen INC. | $24.89 | 2022 | |
| Uswm, LLC | $21.70 | 2021 | |
| Vyne Pharmaceuticals INC. | $20.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Sweet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.